Literature DB >> 31282975

Prevalence of Skin-specific Autoantibodies in HIV-infected Patients and Uninfected Controls.

Veronique Touzeau-Roemer1, Michael Skoll, Pooja Tajpara, Philip Kienzl, Antonia Wesinger, Simona Saluzzo, Martin Bauer, Maximilian C Aichelburg, Christine Bangert, Wolfgang Bauer, Georg Stingl, Armin Rieger, Katharina Grabmeier-Pfistershammer, Christopher Schuster.   

Abstract

Various autoantibodies are detected more frequently in HIV-infected individuals than in HIV-negative controls; however, limited data exist regarding autoimmune blistering skin diseases. Using enzyme-linked immunoassay (ELISA) and indirect immunofluore-scence, no difference in the frequency and magnitude of autoantibodies against BP180, BP230, desmoglein 1 and 3 was found between 594 HIV-infected patients and 248 uninfected controls in this cross-sectional study (16.0% vs. 11.7%, respectively, for at least one positive ELISA, p = 0.11). Interestingly, reactive syphilis serology in both HIV-infected individuals and uninfected controls was associated with positive anti-BP180 ELISA results (adjusted odds ratio (OR) 2.14, 95% confidence interval (CI) 1.07-4.29, p = 0.03 and OR 4.70, CI 1.3-16.86; p = 0.0180). Our study shows a comparably low prevalence of cutaneous autoantibodies in both HIV-infected patients and uninfected controls lacking signs of autoimmune blistering skin disease. Positive BP180 ELISA in the absence of clinical signs of bullous pemphigoid should prompt further evaluation for syphilis antibodies.

Entities:  

Keywords:  autoimmune blistering skin disease; bullous pemphigoid; cART; pemphigus; HIV

Mesh:

Substances:

Year:  2019        PMID: 31282975     DOI: 10.2340/00015555-3251

Source DB:  PubMed          Journal:  Acta Derm Venereol        ISSN: 0001-5555            Impact factor:   4.437


  1 in total

1.  Frequency of Envoplakin and Type VII Collagen Autoantibodies and Co-occurrence with Other Skin-specific Autoantibodies in HIV-infected Patients and Uninfected Controls.

Authors:  René Reitermaier; Michael Skoll; Veronique Touzeau-Roemer; Maximilian C Aichelburg; Adelheid Elbe-Bürger; Wolfgang Bauer; Armin Rieger; Christopher Schuster
Journal:  Acta Derm Venereol       Date:  2021-11-24       Impact factor: 3.875

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.